Key Points {#d30e240}
==========

The overall response rate to abrogate status epilepticus (SE) with intravenous (IV) valproate was 70.9 % (601 out of 848 patients; 95 % confidence interval \[CI\] 67.8--73.9), with a most commonly used dose between 15 and 45 mg/kg in bolus (6 mg/kg/min) followed by 1--3 mg/kg/h infusion.The incidence of adverse events was low overall (\<10 %), mainly dizziness, thrombocytopenia, and mild hypotension, which was independent of infusion rates, and a good cardiovascular and respiratory tolerability even in high doses and fast infusion rates up to 30 mg/kg at 10 mg/kg/min.Given the low incidence of clinically relevant adverse events, and the potentially serious or even fatal consequences of not abrogating seizure activity rapidly in SE, the ratio of benefit to risk seems clearly in favor of treatment.Though IV valproate appears to be an effective and safe treatment with good tolerability in SE, there is an urgent need for high-quality randomized controlled trials to inform clinicians on the best treatment in SE.

Introduction {#Sec1}
============

Status epilepticus (SE) can be defined as "a condition characterized by an epileptic seizure that is so frequent or so prolonged as to create a fixed and lasting condition" \[[@CR1]\]. In light of the seriousness of the condition and the urge to treat as early as possible to prevent refractory SE, the timeframe has been progressively shortened to a pragmatic definition of 5 min ongoing seizures \[[@CR2]\]. Indeed, if left untreated, SE is potentially fatal or can lead to irreversible brain damage. Population-based studies \[[@CR3]--[@CR8]\] have estimated an incidence of up to 60 cases per 100,000 per year, with the highest incidence in young children and the elderly \[[@CR9]\]. Thus, it represents one of the most common neurological emergencies.

There is general agreement that treatment of SE should follow a staged treatment protocol \[[@CR10]\]. Randomized controlled trials show that intravenous lorazepam \[[@CR11]--[@CR13]\] or intramuscular midazolam \[[@CR14], [@CR15]\] are the most efficient treatment in early status. Approximately 30--40 % of all patients fail to respond to initial treatment with benzodiazepines and need further treatment with intravenous antiepileptic drugs (AEDs). A high proportion of these remain refractory, necessitating the use of anesthetics \[[@CR12], [@CR16]--[@CR18]\]. Intravenous phenytoin or phenobarbital is widely used as treatment for established status. However, these drugs are not efficacious in several epilepsy syndromes and there are tolerability issues associated with their use. Both phenobarbital and phenytoin may cause cardiac arrhythmias, hypotension, and respiratory depression, the latter being aggravated by co-administration with benzodiazepines \[[@CR17]\].

Intravenous formulations of other AEDs, including valproate, levetiracetam, and lacosamide have generated considerable interest in their potential use for the treatment of established SE after failure of benzodiazepines \[[@CR19]--[@CR22]\]. The first case reports demonstrating the utility of valproate administered rectally for controlling SE go back to the late 1970s \[[@CR23]--[@CR26]\] and continued to be described throughout the 1980s and 1990s \[[@CR27]\] until intravenous valproate was introduced \[[@CR19], [@CR28]\].

The fact that SE generally occurs without warning, and the need to treat SE as a medical emergency, means that classical randomized clinical trials corresponding to contemporary regulatory standards are extremely challenging to perform. Thus, there are no class I data to support treatment recommendations on the choice of AED for established and refractory SE. Nonetheless, the published literature contains extensive information on the efficacy and safety of intravenous valproate in the treatment of SE, which has been used as the basis for regulatory approval of this treatment in such selected countries as Norway and Germany.

This article provides a systematic literature review of the current evidence for the efficacy and tolerability of valproate in the treatment of SE.

Methods {#Sec2}
=======

A comprehensive review of the literature and searches to find unpublished trials was performed to minimize publication bias. The electronic database MEDLINE (January 1966--19 March 2013; accessed by PubMed) was comprehensively searched. The medical subject heading (MeSH) terms 'valproic acid' and 'status epilepticus', as well as the following free terms were used in multiple search strategies with Boolean operators to find relevant articles published until 19th March 2013: 'valproate', 'valproic acid', and 'status epilepticus'.

The following search strategy was applied: (('valproic acid' \[MeSH\] OR valpro\* OR valproic acid OR valproate) AND ('status epilepticus' \[MeSH\] OR status epilepticus)).

All resulting titles and abstracts were evaluated, and any relevant article was considered. There were no language restrictions.

All identified studies were cross referenced to identify any reports that may have been missed. The manufacturer of valproate (Sanofi-Aventis) was asked for any reports of further unpublished studies. For the analysis of efficacy, case reports were excluded, since it is not possible to determine response rates from individual cases. For the same reason, studies in which multiple AEDs were evaluated without presentation of results for individual AEDs were also excluded. Studies using intravenous valproate as first-line treatment or after failure of first-line benzodiazepines (lorazepam or diazepam) were considered eligible. For each study, response rates were extracted as the proportion of patients whose seizures resolved after valproate treatment. Seizure resolution was most frequently adopted in the studies as outcome for efficacy. However, cessation of seizure activity, or AED efficacy, was defined differently by different authors in the selected studies; some were based on termination of seizures alone and others based on a lack of recurrence for a certain period of time. Furthermore, in some studies, seizure resolution was based on clinical signs alone and in other studies on the assessment of electrographic seizure activity.

The frequency of adverse events reported in the studies, particularly hypotension and respiratory depression, was used for the analysis of safety; the worldwide pharmacovigilance database of Sanofi-Aventis was also interrogated to identify reported adverse events.

Results {#Sec3}
=======

Studies Identified {#Sec4}
------------------

The search strategy yielded 433 results (425 MEDLINE, seven congress abstracts, one unpublished study). After excluding duplicate publications and case reports, 55 articles were provisionally selected. We excluded 25 studies after reading the full published papers; thus, 30 studies contributed to this review: the earliest was published in 1993 and the most recent in 2012.

Overall, we identified through a comprehensive search in MEDLINE 25 publications in which the efficacy of intravenous valproate in SE had been reported \[[@CR29]--[@CR53]\]. Cross-referencing identified seven additional reports in congress abstracts \[[@CR54]--[@CR60]\]. Three of these were redundant \[[@CR55], [@CR57], [@CR60]\] as they corresponded to case series subsequently described in full publications as part of larger cohorts \[[@CR35], [@CR40], [@CR45]\]. Finally, the manufacturer of valproate provided the clinical study report of an unpublished study \[[@CR61]\].

Of the 30 unique studies identified, six were randomized controlled trials, none of them blinded, comparing intravenous valproate to phenytoin, diazepam, or phenobarbital \[[@CR41]--[@CR43], [@CR46], [@CR52], [@CR53]\], and four non-randomized controlled studies comparing intravenous valproate to phenytoin or levetiracetam \[[@CR48]--[@CR51]\]. One randomized controlled trial also included patients with acute repetitive seizures not entailing the diagnosis of SE. For this study, information from patients with SE was obtained from a systematic review \[[@CR62]\]. Of the uncontrolled studies, eight were prospective observational studies and 12 were retrospective case series.

### Randomized Controlled Studies {#Sec5}

Three randomized controlled studies compared intravenous valproate with intravenous phenytoin \[[@CR41], [@CR42], [@CR46]\], two with intravenous diazepam \[[@CR43], [@CR52]\], and one with intravenous phenobarbital \[[@CR53]\]. These studies included 361 patients (183 were randomized to receive valproate; Table [1](#Tab1){ref-type="table"}; Fig. [1](#Fig1){ref-type="fig"}). The phenobarbital study \[[@CR53]\] and one diazepam study \[[@CR43]\] included only children; one phenytoin study \[[@CR46]\] included only adults, whereas the remaining studies \[[@CR41], [@CR42], [@CR52]\] included all age groups. The most frequent SE was generalized convulsive. Valproate was administered most often at an initial bolus dose of 20 or 30 mg/kg (Table [2](#Tab2){ref-type="table"}).Table 1Randomized comparative studies evaluating intravenous valproate monotherapy in the treatment of status epilepticus. Studies are listed in decreasing order of sample size. All studies were carried out as single-center open-label trials, except Malamiri et al., which was conducted in two centersReferences*N*PatientsType of SEDose regimenAgarwal et al. \[[@CR42]\]V: 50, P: 5062 adults/38 children (\<18 y), 67 male/33 femalePrimary generalized seizures: 14, JME: 2V: Initial bolus 20 mg/kg at 40 mg/min, P: Initial bolus 20 mg/kg at up to 50 mg/minMisra et al. \[[@CR41]\]V: 35, P: 33Adults and children (1--85 y), 41 male/27 femaleConvulsive SE (unspecified)V: Initial bolus 30 mg/kg in 100 ml over 15 min, P: Initial bolus 18 mg/kg in 100 ml infused at 50 mg/minGilad et al. \[[@CR46]\]V: 18, P: 9Adults (\>18 y), 19 male/7 femaleGTC SEV : Initial bolus 30 mg/kg in 50 ml of saline over 20 min, P: Initial bolus of 18 mg/kg in 100 ml of saline over 20 minChen et al. \[[@CR47]\]V: 30, D: 36Children and adults (\>15 y), 36 male/30 femaleGTC and sGTC SEV: Initial bolus 30 mg/kg at 6 mg/kg/min followed by continuous infusion at 1--2 mg/kg/h, D: Initial (third) bolus of 0.2 mg/kg at 5 mg/min followed by infusion at 4 mg/h for 3 min and then increased every 3 min by 1 µg/min until seizure control or maximal duration (1 h) reachedMehta et al. \[[@CR43]\]V: 20, D: 20Children (≤12 y) (mean 3.7), 31 boys/9 girlsGTC SE: 18, sGTC SE : 12, Simple focal SE: 8, Multifocal : 2V: Initial bolus 30 mg/kg over 2--5 min; if SE uncontrolled, repeat bolus then infusion at 5 mg/kg/h, D: 10 µg/kg/min initial infusion increased by 10 µg/kg/h every 5 min if SE uncontrolled up to 100 µg/mg/kgMalamiri et al. \[[@CR53]\]V: 30, B: 30Children (\>2 y) (median 5, range 3--16), 37 boys/23 girlsConvulsive SE (all subtypes)V: Initial bolus 20 mg/kg in 20 ml saline at max. 5--6 mg/kg/min over 5--10 min, B: Initial bolus 20 mg/kg at max. 60--100 mg/min*B* phenobarbital, *D* diazepam, *GTC* generalized tonic--clonic, *JME* juvenile myoclonic epilepsy, *P* phenytoin, *SE* status epilepticus, *sGTC* secondary generalized tonic--clonic, *V* valproateFig. 1Intravenous valproic acid versus intravenous phenytoin, and intravenous valproic acid versus intravenous diazepam. Outcome: seizure cessation after drug administration. Analyses performed using Review Manager 5.2 (available at: <http://tech.cochrane.org/revman/download>). *CI* confidence interval, *DZP* diazepam, *IV* intravenous, *PHT* phenytoin, *VPA* valproic acidTable 2Non-randomized comparative studies evaluating intravenous valproate monotherapy in the treatment of SEReferences*N*PatientsType of SEDose regimenTripathi et al. \[[@CR49]\]V: 41, L: 41Adults (\>14 y), 42 male/40 femaleRefractory GTC SEV: Initial bolus 30 mg/kg at 5 mg/kg/min, L: initial bolus 30 mg/kg at 5 mg/kg/minTiamkao and Sawanyawisuth \[[@CR48]\]V: 32, P: 37^a^Adults (\>15 y), No information on genderGTC SEV: Initial bolus 15--25 mg/kg with max infusion rate of 50 mg/min, P: Initial bolus 15--20 mg/kg with max infusion rate of 50 mg/minKalita et al. \[[@CR50]\]V: 65, P: 5222 children (≤12 y), 95 adults, 73 male/44 femaleGTC SE: 108, NCSE: 9V: Initial bolus 30 mg/kg, P: Initial bolus 20 mg/kgAlvarez et al. \[[@CR51]\]V: 59, P: 70, L: 58Adults (\>16 y), No information on genderSE (all subtypes including NCSE)V: Initial bolus 20 mg/kg with maintenance dosage 1,000--2,500 mg/day, P: Initial bolus 20 mg/kg with maintenance dosage 300--400 mg/day, L: Initial bolus 20 mg/kg with maintenance dosage 1,000--3,000/dayStudies are listed in decreasing order of sample size^a^12 and 20 patients received intravenous valproate as the first- and second-line therapy, respectively*GTC* generalized tonic--clonic, *L* levetiracetam, *NCSE* non-convulsive status epilepticus, *P* phenytoin, *SE* status epilepticus, *V* valproate

### Non-Randomized Controlled Trials {#Sec6}

Non-randomized controlled studies were included in the present review. Two studies utilized a prospective design \[[@CR49], [@CR50]\], and two were retrospective \[[@CR48], [@CR51]\]. These studies included 455 subjects (197 were randomized to valproate; Table [1](#Tab1){ref-type="table"}).

### Prospective Open-Label Studies {#Sec7}

The eight prospective studies identified are presented in Table [1](#Tab1){ref-type="table"}. Overall, these included 191 patients with SE treated with intravenous valproate (135 adults, 46 children, and ten of unspecified age). These studies all evaluated intravenous valproate administered in monotherapy, usually administered as a bolus (15--40 mg/kg) followed by a maintenance infusion.

### Retrospective Case Series {#Sec8}

We identified 12 retrospective case series (Table [3](#Tab3){ref-type="table"}). These included 76 adults, 45 children, and 135 subjects of unspecified age with SE. Again, valproate was usually administered as a bolus (15--40 mg/kg) followed by a maintenance infusion.Table 3Prospective open-label studies evaluating intravenous valproate monotherapy in the treatment of status epilepticusReferences*N*PatientsType of SEDose regimenOlsen et al. \[[@CR45]\]41Adults (20--85 y)\
18 men/23 womenGTC SE: 19\
Complex partial SE: 16\
Unclassifiable: 6Initial bolus 25 mg/kg over 30 min\
Followed by infusion 100 mg/h for ≥24 h\
Median bolus dose 1,800 mg (range 700--2,500 mg)Überall et al. \[[@CR33]\]41Children (≤16 y)\
27 boys/14 girlsGTC SE: 10\
sGTC SE: 9\
Absence status: 5\
Infantile spasms: 4\
Neonatal SE: 5\
EPC: 2\
Complex partial SE: 6Initial bolus 20--40 mg/kg over 1--5 min\
Repeated after 10--15 min if necessary\
Then 5 mg/kg/h infusionGiroud et al. \[[@CR29]\]23Adults (17--80 y)\
13 men/10 womenGTC SE: 8\
GMC SE: 2\
PM SE: 10\
PMC SE: 1\
Absence status: 2Initial bolus 15 mg/kg\
Followed 30 min later by infusion at 1 mg/kg/h\
Mean total dose: 19.4 mg/kgCzapiński and Terczyński \[[@CR30]\]20Adults (16--76)\
11 men/9 womenSimple partial SE: 11\
GTC SE: 9Initial bolus 15 mg/kg\
Followed 30 min later by infusion at 1 mg/kg/h for 24 hRamsay et al. \[[@CR65]\]10Age and gender not specifiedNot specifiedBolus infusion 20--30 mg/kg at 0.3--0.5 mg/kg/min\
Total dose up to 3,000 mg within 12 minLeninger and Hofnagel \[[@CR56]\]6Adults (23--70)\
All womenNCSE900--3,000 mg/24 h infusion over 2 daysNarayanan and Murthy \[[@CR44]\]^a^22 (2)^a^3 children/19 adults\
11 male/11 female (2 adult women)NCSE\
(2 absence status)Not specifiedChen et al. \[[@CR47]\]485 children (\<15 y) and 43 adults (\>15 y)\
19 male/29 femaleGTC SE: 30\
sGTC SE: 14\
TSE: 4Initial bolus of 15 mg/kg over 5 min (repeated 10--15 min later if necessary), followed by continuous infusion at 30 mg/kg, infused at an hourly rate of 6 mg/kg^a^The figures in brackets refer to subjects receiving intravenous valproate monotherapy in studies where more than one AED was studied*EPC* epilepsia partialis continua, *GMC* generalized myoclonic, *GTC* generalized tonic--clonic, *NCSE* non-convulsive status epilepticus, *PM* partial motor, *PMC* partial myoclonic, SE status epilepticus, *sGTC* secondary generalized tonic--clonic, *TSE* tonic status epilepticus

Seizure Outcome {#Sec9}
---------------

Response rates are presented in Table [4](#Tab4){ref-type="table"}. These rates varied across studies, between 35 and 100 % (median 74.35 %). The overall response rate in all studies was 70.9 % (601/848; 95 % confidence interval \[CI\] 67.8--73.9). Outcome in children (81.3 %; 104/128; 95 % CI 74.5--88) was better than in adults (68.5; 207/302; 95 % CI 63.3--73.8). Response rate was lower in controlled non-randomized studies (61.8 %, 114/185; 95 % CI 54.6--66.6) than in randomized controlled studies (75.4 %; 138/183; 95 % CI 69.2--81.6) or retrospective case series (68.2 %; 197/289; 95 % CI 62.8--73.8). There was no difference in response rates in convulsive (69.7 %; 246/353; 95 % CI 64.9--74.5) compared with non-convulsive SE (75 %; 15/20; 95 % CI 56--94), although the comparison is limited by the small number of studies in which outcome was presented according to SE type.Table 4Retrospective case series evaluating intravenous valproate monotherapy in the treatment of status epilepticusReferences*N*PatientsType of SEDose regimenLimdi et al. \[[@CR39]\]63Age range not specified\
30 men/33 womenNot specifiedBolus 10--78 mg/kg until serum levels reach 278 mg/lCzapiński \[[@CR54]\]120 (40)^a^Age and gender not specifiedNot specifiedInitial bolus 15 mg/kg\
Followed by infusion at 1 mg/kg/hPeters and Pohlmann-Eden \[[@CR40]\]35Adults (18--85 y)\
18 men/17 womenGTC SE: 6\
Simple partial: 12\
Complex partial: 14\
Absence status: 3Bolus infusion 4--16 mg/kg for 5--10 min\
Followed by infusion of 0.5--4 mg/kg/h for 4 h to 6 daysNaritoku \[[@CR34]\]32Mean age 68.5 y\
Gender unspecifiedGTC SE: 12\
Other: 20Bolus infusion 25 mg/kg\
Mean serum concentration 80.1 mg/lRosenow and Knake \[[@CR35]\]27Adults (22--94 y)\
Gender unspecifiedsGTC SE: 11\
Partial SE: 7\
Absence status: 2Bolus infusion 300--800 mg (mean 1,000 mg)\
Followed by infusion of 1,200--1,800 mg/24 hCampistol et al. \[[@CR31]\]19Children (≤7 y)\
10 boys/9 girlsIG SE: 4\
SP SE: 2\
Other secondary: 17Initial bolus 20 mg/kg\
Followed by infusion at 1 mg/kg/hYu et al. \[[@CR37]\]40\
(18)^a^Children (≤19 y)\
Gender unspecifiedNot specifiedBolus infusion 25 mg/kg at 2.8 mg/kg/minKatragadda et al. \[[@CR32]\]121 child, 11 adultsPartial NCSE: 9\
Absence status: 3Not specifiedPrice \[[@CR61]\]116 children (6--17 y)\
5 adults (26--72 y)\
7 male/4 femaleNot specifiedNot standardizedJha et al. \[[@CR36]\]112 children (7, 15 y)\
9 adults (24--60 y)\
7 male/4 femaleGTC SE: 1\
EPC: 5\
Myoclonic SE: 4\
NCSE: 1Bolus infusion 20 mg/kg at 20 mg/min\
Repeated as necessaryPatel and Jha \[[@CR38]\]10Adults (18--60 y)\
3 men/7 womenPost-anoxic myoclonic SEBolus infusion 20 mg/kg at 20 mg/min\
Followed by 10 mg/kg every 6 h for 24 hShort \[[@CR59]\]22 (7)^a^All ages (2--75 y)\
Mean age 40 yNot specifiedMean initial dose: 1,020 ± 946 mg\
Mean total dose: 19,017 ± 30,196 mg\
Mean infusion rate: 21 ± 13 mg/min^a^The figures in brackets indicate the number of subjects receiving intravenous valproate monotherapy*EPC* epilepsia partialis continua, *GTC* generalized tonic--clonic, *IG* idiopathic generalized, *NCSE* non-convulsive status epilepticus, *SE* status epilepticus, *sGCT* secondary generalized tonic--clonic, *SP* simple partial

### Comparative Randomized Studies {#Sec10}

Six studies have compared the efficacy of intravenous valproate with that of intravenous phenytoin, diazepam, or phenobarbital. Two studies compared valproate with phenytoin in early SE \[[@CR43], [@CR46]\], whereas one study compared valproate with phenytoin in established SE \[[@CR42]\].

In the first study \[[@CR41]\] comparing the rate of response, defined as seizure cessation at the end of the infusion, it was significantly (*p* = 0.046) higher in the valproate group (66 %; *n* = 35) than in the phenytoin group (42 %; *n* = 33). Non-responders were switched to the other treatment, where 15 of 19 non-responders to phenytoin (79 %) responded to valproate compared with 3 of 12 non-responders to valproate (12 %) who responded to phenytoin (*p* = 0.004). Seizure freedom at 24 h was obtained in 29 patients, irrespective of treatment group or sequence. However, the use of a maintenance AED regimen after the bolus infusion was not reported in this study.

In the second study \[[@CR46]\], treatment success was defined as clinical seizure cessation after infusion without need for rescue medication within 20 min of the infusion. No statistically significant difference in the rate of treatment success was found among patients treated with valproate (13 of 18; 72.2 %) and phenytoin (seven of nine patients; 77.8 %). Seizure freedom at 24 h was obtained in all patients (100 %) in both groups.

In the study comparing valproate with phenytoin in established SE, treatment success was defined as cessation of all motor and electroencephalography (EEG) seizure activity within 20 min of starting drug infusion and no return of seizure activity in the following 12 h \[[@CR42]\]. According to this criterion, 44 patients receiving valproate (88 %) and 42 receiving phenytoin (84 %) experienced treatment success. Success rates were higher in patients in whom SE had been treated within 2 h (*p* \< 0.05), with only one such patient treated with phenytoin failing to respond.

In the study comparing valproate with diazepam, both in children and in adults, generalized convulsive SE was controlled in 56 % (20 of 36 patients) of the diazepam group and 50 % (15 of 30 patients) in the valproate group \[[@CR52]\]. Relapse of SE within 24 h occurred in 25 % (5 of 20 patients) of the diazepam and 20 % (3 of 15 patients) of the valproate group. Both failed to reach statistical significance, suggesting no differences between groups in terms of efficacy.

A recent systematic review assessing the role of valproate in generalized convulsive SE included the above-mentioned studies comparing intravenous valproate with intravenous phenytoin \[[@CR41], [@CR42], [@CR46]\] in a meta-analysis \[[@CR62]\]. Compared with phenytoin, intravenous valproate had no statistically significant differences in seizure cessation after drug administration (risk ratio \[RR\] 1.31, 95 % CI 0.93--1.84) and in seizure freedom at 24 h (RR 0.96, 95 % CI 0.88--1.06).

In the study comparing valproate with diazepam in children, SE was successfully controlled in 16/20 patients receiving valproate (80 %) and 17/20 patients receiving diazepam (85 %) \[[@CR43]\]. The median time to abrogation of seizure activity was shorter (*p* \< 0.001) in the valproate (5 min) than in the diazepam group (17 min). Breakthrough seizures during the maintenance phase occurred in eight patients in each group.

In the study comparing intravenous valproate with intravenous phenobarbital in children, treatment success was defined as cessation of all convulsive activity within 20 min of anticonvulsant infusion \[[@CR53]\]. Seizure termination was significantly higher among patients treated with intravenous loading of valproate (27 of 30 patients; 90 %) than in patients treated with phenobarbital (23 of 30 patients; 77 %) (*p* = 0.189). In the phenobarbital group, a statistically significant higher relapse of SE within 24 h was observed (12 of 23 children) compared with valproate treatment (4 of 27 children).

### Comparative Non-Randomized Studies {#Sec11}

Four studies have compared the efficacy of intravenous valproate with that of intravenous phenytoin or levetiracetam \[[@CR48]--[@CR51]\].

One prospective study compared intravenous valproate with intravenous levetiracetam in adults with refractory SE at a tertiary center in India \[[@CR49]\]. Refractory SE was defined as seizures lasting for more than 1 h, and patients had to have already received intravenous lorazepam and phenytoin. Clinical seizure cessation after infusion was obtained by 26 of 41 patients in the valproate group (68.3 %) and 28 of 41 patients in the levetiracetam group (73.2 %), although the difference was not statistically significant. Seizure control was not reached by 13 (31.7 %) patients in the valproate group and 11 (26.8 %) in the levetiracetam group (difference not statistically significant), and patients required intubation and administration of propofol or midazolam infusion.

One retrospective study was conducted in adults with convulsive SE who were treated with intravenous valproate as first- or second-line AED \[[@CR48]\]; 12 (24 %) and 37 (76 %) patients were treated with intravenous valproate and phenytoin as first-line treatment, respectively. Treatment success was defined as the cessation of seizures by either clinical or EEG evidence. SE ceased in 9 of 12 patients (75 %) with intravenous valproate and 17 of 37 patients (46 %) with intravenous phenytoin as first-line treatment (difference not statistically significant), whereas it ceased in 7 of 20 (35 %) patients who received second-line valproate.

Kalita et al. \[[@CR50]\] conducted a prospective study in children and adults with convulsive and non-convulsive SE, comparing first-line intravenous valproate with first-line intravenous phenytoin. A total of 65 patients received valproate and 52 received phenytoin as a first-line AED, which resulted in control of SE in 56 % of patients with valproate and 44 % of patients with phenytoin. Crossing over of the treatment in uncontrolled patients resulted in seizure cessation in 41 additional patients, whereas 35 (30 %) remained refractory to both valproate and phenytoin. Within 24 h, seizures recurred in six patients whose SE initially responded to the first or second AED (no further information on valproate or phenytoin was available in the published article).

A retrospective study compared intravenous valproate with phenytoin or levetiracetam as second-line treatment in adults \[[@CR51]\]. The primary outcome was the failure of the second-line AED, defined as the need to introduce a further compound to control SE; 15 of 59 patients in the valproate group (25.4 %) failed to control seizures, compared with 29 of 70 patients in the phenytoin group (41.4 %) and 28 of 58 patients in the levetiracetam group (48.3 %).

### Status Epilepticus (SE) Subtypes {#Sec12}

Certain studies have reported seizure outcome in response to intravenous valproate treatment in defined seizure types.

#### Generalized Tonic--Clonic SE {#Sec13}

The largest group of patients for whom seizure outcome has been reported by seizure type corresponds to patients presenting with generalized tonic-clonic SE. Specific outcome was reported in ten studies \[[@CR29], [@CR30], [@CR33], [@CR34], [@CR36], [@CR40], [@CR45], [@CR47], [@CR49], [@CR52]\], including a total of 166 patients. Most subjects (119/166) responded to treatment, yielding an overall response rate of 71.7 % (95 % CI 68.3--75.1).

#### Focal SE {#Sec14}

The other type of SE in which intravenous valproate has been most frequently evaluated is simple or complex focal SE. Overall, data have been reported for 107 patients, included in nine studies \[[@CR29]--[@CR31], [@CR33], [@CR34], [@CR36], [@CR45], [@CR47], [@CR57]\]. Most subjects (83/107) responded to treatment, with an overall response rate of 77.6 % (95 % CI 75.3--79.9).

#### Absence Status {#Sec15}

Information on the effectiveness of monotherapy with intravenous valproate in absence status is limited. Such patients have been reported in six studies \[[@CR29], [@CR32], [@CR33], [@CR36], [@CR44], [@CR57]\]. The number of subjects in these studies was low (16 overall, ranging from one to five patients per study). In all studies except one \[[@CR57]\], including three patients in whom absence status was described as atypical, SE was rapidly abrogated by valproate treatment in the majority of cases (12/16 cases). The overall response rate in absence status was 75.0 % (95 % CI 53.8--96.2). In one study, two patients with absence status received valproate as first-line therapy rather than after failure of intravenous benzodiazepines \[[@CR44]\]. Both of these patients responded to treatment.

#### Other Presentations of SE {#Sec16}

Three patients with myoclonic SE were studied by Giroud et al. \[[@CR29]\] and four such patients by Jha et al. \[[@CR36]\]. One patient in each study failed to respond. The overall success rate was thus 71 %. Patel and Jha \[[@CR38]\] reported ten patients with post-anoxic myoclonic SE occurring after surgery. SE was abrogated successfully in six of these patients (60 %) with intravenous valproate given at a dose of 30 (four patients) or 40 (two patients) mg/kg within 2--10 h. In addition to these patients, two cases of successful treatment of myoclonic SE have been reported by Sheth and Gidal \[[@CR63]\]. Überall et al. \[[@CR33]\] reported two cases of status associated with infantile spasms; both responded successfully to intravenous valproate therapy.

### Seizure Outcome and Order of Valproate Administration {#Sec17}

Two randomized \[[@CR41], [@CR46]\] and one non-randomized \[[@CR50]\] controlled trials used valproate as first-drug antiepileptic treatment instead of benzodiazepines. Four randomized \[[@CR42], [@CR43], [@CR52], [@CR53]\] and three non-randomized \[[@CR48], [@CR49], [@CR51]\] controlled trials used valproate after failure of first-line benzodiazepines (lorazepam or diazepam).

Among studies using valproate as second-line drug, SE was controlled in 50--90 % of patients allocated to valproate in randomized controlled studies, and in 56 % of patients treated with valproate in the non-randomized controlled trial. Among studies using valproate as first-line drug, SE was controlled in 66--72.2 % of patients allocated to valproate in randomized controlled studies, and in 68.3--75 % of patients treated with valproate in non-randomized controlled trials.

Safety {#Sec18}
------

Information on the safety of intravenous valproate derives from a limited number of dedicated safety studies, adverse event reporting in the efficacy studies described above, individual case reports, and pharmacovigilance reporting.

### Dedicated Safety Studies {#Sec19}

A number of dedicated studies have investigated the safety of intravenous valproate in patients with epilepsy during the clinical development of this formulation. Not all of these studies concern patients with SE, but the data obtained are nonetheless pertinent to the risk--benefit assessment of intravenous valproate in SE.

The largest of these studies included 318 patients, both children and adults, with epilepsy and hospitalized for seizure-related reasons \[[@CR64]\]. The initial dose was 15 mg/kg/day in four divided doses every 6 h. Subsequent doses were adjusted at the discretion of participating investigators as a function of serum valproate concentrations. The median dose of valproate administered was 375 mg infused over 1 h. The median number of doses was four, given over 2 days. Transient adverse events were reported in 54 patients (17.5 %), most frequently headache, injection-site reactions, nausea, somnolence, vomiting, dizziness, and taste perversion. None were reported in more than seven patients (2.3 %). No changes in hematological parameters, blood chemistry, or vital signs were observed.

A second large study compared infusion of valproate at either 1.5 or 3 mg/kg/min in 112 hospitalized children or adults with epilepsy \[[@CR65]\]. The maximum dose per infusion permitted was 15 mg/kg, and the maximum number of infusions per 24 h period was four. The primary outcome was changes in blood pressure during and after the first valproate infusion. Although no change in mean blood pressure was observed in the sample as a whole, two subjects infused at a rate of 3 mg/kg/min presented transient hypotension. The most common adverse events reported were somnolence, paresthesia, dizziness, and nausea. None of the patients had any alteration of consciousness. A possibly treatment-related case of encephalopathy was reported as a serious adverse event in a patient receiving valproate at an infusion rate of 3 mg/kg/min (peak serum valproate concentration of 123 µg/ml), which resolved upon discontinuation of valproate. No clinically significant abnormalities in blood chemistry or hematology were noted.

A number of other smaller safety studies \[[@CR66]--[@CR69]\] have reported adverse event profiles similar to these two large studies. In addition, one case of asymptomatic hyperammonemia has been described \[[@CR66]\]. More recently, a prospective study on 40 patients receiving an intravenous loading dose of 20 mg or 30 mg at 6 mg or 10 mg/kg/min of valproate found asymptomatic hyperammonemia in 30 of 40 patients 1 h after the infusion, decreasing to 66 % at 24 h after infusion \[[@CR70]\]. None of the patients had any alteration of consciousness or increase of transaminases.

Concerning more rapid injection schedules, one study \[[@CR68]\] compared blood pressure changes and adverse events between 36 patients infused at a rate of 3 mg/kg/min up to a maximum dose of 15 mg/kg, 24 patients infused at 3 mg/kg/min up to 30 mg/kg, and six patients infused at 6 mg/kg/min up to 15 mg/kg. No increase in the incidence of adverse events was seen with the higher dose or faster infusion rate, and no changes in blood pressure were observed. Subsequently, infusion rates of up to 11 mg/kg/min have been reported in pediatric patients, with no untoward safety issue being identified \[[@CR71]\].

Since hypotension is a concern with other intravenous AED treatments for SE, such as phenytoin, a retrospective analysis has been performed of the hemodynamic effects of intravenous valproate used to control SE in 13 patients with antecedents of hypotension or cardiovascular instability \[[@CR72]\]; 12 of these patients were elderly (\>64 years). The mean loading dose of intravenous valproate was 25.1 ± 5.0 mg/kg infused at a rate of 36.6 ± 25.1 mg/min, which produced serum valproate concentrations after completion of the infusion of 78.7 ± 35.8 mg/l. All except one patient received vasopressors (dopamine or dobutamine) before the valproate infusion began. No significant changes in systolic or diastolic blood pressure were observed during or after valproate infusion, and increases in vasopressor dose were not required. No other cardiovascular adverse effects or changes in cardiac rhythm were observed.

An open-label, prospective trial evaluated the safety of rapid intravenous loading of undiluted valproate (20 or 30 mg/kg/min at rates of 6 or 10 mg/kg/min) in 40 patients with epilepsy \[[@CR69]\]. Rapid administration of valproate was well tolerated, with no significant changes in heart rate and mean arterial pressure by dose group (20 mg/kg, 30 mg/kg) across time (measurements at 20, 30, 45, 60, and 240 min after administration). No patient exhibited alteration of consciousness at 30--60 min after dose administration compared with baseline, although three patients (7.5 %) complained of sedation and one of nausea. There were no disturbances in cardiac conduction or arrhythmias as indicated by normal electrocardiogram (ECG) in all patients at all time points. A total of 30 patients (81.5 %) complained of local irritation (pain/burning or paresthesias) lasting less than 3 min, with no indication of redness, irritation, or phlebitis. No significant changes in platelets or hepatic parameters were observed.

Although this study was not conducted in patients with SE, rapid administration of undiluted valproate proved safe and well tolerated, supporting its use in emergent situations.

The risk of local injection-site reactions with intravenous valproate was explored specifically in a retrospective chart review of two double-blind randomized clinical trials evaluating the use of valproate or phenytoin to prevent post-traumatic seizures in 775 patients with traumatic brain injury \[[@CR73]\]. Injection-site reactions occurred in 18 % of patients receiving valproate and 25 % of those receiving phenytoin, for the most part during administration of the initial loading dose. When only patients receiving the drugs by a peripheral line were taken into account, the frequency of injection-site reactions with valproate and phenytoin was 21 and 30 %, respectively (*p* = 0.056). No cases of skin necrosis or purple glove syndrome were observed in both groups. However, other studies reported an incidence of purple glove syndrome of 1.7--5.9 % after phenytoin administration \[[@CR74], [@CR75]\].

### Comparative Randomized Studies {#Sec20}

The six comparative randomized studies included 183 patients treated with valproate. The incidence of hypotension and respiratory depression was reported in all six studies, and the incidence of hepatic abnormalities in two studies. The overall rate of these three adverse events in patients treated with intravenous valproate was 0.5, 0.5, and 3.8 %, respectively (Table [5](#Tab5){ref-type="table"}). The incidence of hypotension and respiratory depression was lower with valproate than with phenytoin (8.7 and 4.3 %, respectively) or diazepam (21.4 and 25 %, respectively). Conversely, the incidence of hypotension was equal to that of intravenous phenobarbital (0 %), whereas the incidence of respiratory depression was lower for valproate than that reported for intravenous phenobarbital (3.3 %). On the other hand, the incidence of liver abnormalities was higher than that reported for intravenous phenytoin (2.2 %). Given the low patient numbers, none of the differences reported in the individual studies were statistically significant.Table 5Seizure outcome in patients receiving intravenous valproate monotherapy for the treatment of status epilepticusStudyAge groupSE typeDefinition of 'responders'Responders/*N* ^a^% (95 % CI)Comparative randomized studies Agarwal et al. \[[@CR42]\]MixedCSEClinical or EEG seizure cessation within 20 min of infusion44/5088.0 (79--97) Misra et al. \[[@CR41]\]MixedCSEClinical seizure cessation after infusion23/3565.7 (50--81.4) Gilad et al. \[[@CR46]\]AdultsCSEClinical seizure cessation within 20 min of infusion13/1872.2 (51.5--92.9) Chen et al. \[[@CR47]\]MixedCSEClinical seizure cessation after infusion15/3050.0 (32.1--67.9) Mehta et al. \[[@CR43]\]ChildrenCSEClinical seizure cessation after infusion16/2080.0 (62.5--97.5) Malamiri et al. \[[@CR53]\]ChildrenCSEClinical seizure cessation after infusion within 20 min of infusion27/3090.0 (79.3--100)Comparative non-randomized studies Tripathi et al. \[[@CR49]\]AdultsCSEClinical seizure cessation after infusion26/4168.3 (48.7--78.2) Tiamkao and Sawanyawisuth \[[@CR48]\]AdultsCSEClinical seizure cessation within 30 min of infusion9/12^b^75 (50.5--99.5)7/20^b^35 (14.1--55.9) Kalita et al. \[[@CR50]\]MixedMixedClinical seizure cessation after infusion37/6556.9 (44.9--69) Alvarez et al. \[[@CR51]\]AdultsMixedNo additional AEDs needed for ≥48 h after clinical and EEG seizure cessation44/5974.6 (63.5--85.7)Prospective studies Olsen et al. \[[@CR45]\]AdultsMixedClinical seizure cessation after infusion31/4175.6 (62.5--88.8) Überall et al. \[[@CR33]\]ChildrenMixedClinical seizure cessation after infusion32/4178.0 (65.4--90.7) Giroud et al. \[[@CR29]\]AdultsMixedClinical seizure cessation within 20 min of infusion19/2382.6 (67.1--98.1) Czapiński and Terczyński \[[@CR30]\]AdultsCSEClinical seizure cessation within 30 min of infusion16/2080.0 (62.5--97.5) Ramsay et al. \[[@CR65]\]NRNRNR6/1060.0 (26.6--90.4) Leninger and Hofnagel \[[@CR56]\]AdultsNCSEClinical seizure cessation after infusion4/666.7 (28.9--104.4) Narayanan and Murthy \[[@CR44]\]AdultsNCSEClinical seizure cessation after infusion2/2100 Chen et al. \[[@CR47]\]MixedCSEClinical seizure cessation within 1 h of the infusion42/4887.5 (78.1--96.9)Retrospective case series Limdi et al. \[[@CR39]\]NRNRNo additional AEDs needed for ≥12 h after clinical and/or EEG seizure cessation40/6363.3 (51.6--75.4) Czapiński \[[@CR54]\]NRNRClinical seizure cessation within 30 min of infusion33/4082.5 (70.7--94.3) Peters and Pohlmann-Eden \[[@CR40]\]AdultsMixedClinical seizure cessation within 15 min of infusion27/3577.1 (63.2--91.1) Naritoku \[[@CR34]\]NRCSEClinical seizure cessation after infusion16/3250.0 (32.7--67.3) Rosenow and Knake \[[@CR35]\]AdultsMixedNR12/2744.4 (25.7--63.2) Campistol et al. \[[@CR31]\]ChildrenCSEClinical seizure cessation after infusion11/1957.9 (35.7--80.1) Yu et al. \[[@CR37]\]ChildrenMixedClinical seizure cessation within 20 min of infusion18/18100 Katragadda et al. \[[@CR32]\]MixedNCSENR9/1275.0 (50.5--99.5) Price \[[@CR61]\]MixedNRNR10/1566.7 (42.8--90.5) Jha et al. \[[@CR36]\]MixedMixedClinical seizure cessation within 24--48 h of infusion10/1190.9 (73.9--107.3) Patel and Jha \[[@CR38]\]AdultsCSEClinical seizure cessation after infusion6/1060.0 (29.6--90.4) Short \[[@CR59]\]MixedNRNR5/771.4 (38--104.9)^a^Number of subjects receiving intravenous valproate monotherapy^b^12 and 20 patients received intravenous valproate as the first- and second-line therapy, respectively*AED* anti-epileptic drug, *CI* confidence interval, *CSE* convulsive status epilepticus, *EEG* electroencephalography, *NCSE* non-convulsive status epilepticus, *NR* not reported, *SE* status epilepticus

A recent systematic review assessing the role of valproate in generalized convulsive SE included the studies comparing intravenous valproate with intravenous phenytoin \[[@CR41], [@CR42], [@CR46]\] in a meta-analysis \[[@CR62]\]. Compared with phenytoin, intravenous valproate had a statistically lower risk of adverse effects (considered as a whole) (RR 0.31, 95 % CI 0.12--0.85).

### Comparative Not-Randomized Studies {#Sec21}

The four comparative not-randomized studies included 197 patients treated with valproate. The incidence of hypotension and respiratory depression was reported in only one study, showing no difference between the drugs (0 %) \[[@CR49]\].

### Uncontrolled Studies and Case Series {#Sec22}

Adverse events reported in the other prospective studies and retrospective case series discussed above are presented in Table [6](#Tab6){ref-type="table"}. Interpretation of these studies is limited by the disparate nature of adverse event reporting between studies and incomplete ascertainment. Nevertheless, the nature and frequency of the adverse events described are essentially similar to what was observed in the dedicated safety studies. The most frequently reported side effects were nausea/vomiting, dizziness, and sedation (Tables [7](#Tab7){ref-type="table"} and [8](#Tab8){ref-type="table"}).Table 6Adverse event reporting in six comparative randomized studies of valproate in status epilepticusStudy and adverse eventValproatePhenytoinDiazepamPhenobarbitalAgarwal et al. \[[@CR42]\] Hypotension0/506/50 Respiratory depression0/502/50 Mild elevation of liver enzymes4/500/50Misra et al. \[[@CR41]\] Hypotension0/352/33 Respiratory depression1/352/33 Liver dysfunction3/352/33Gilad et al. \[[@CR46]\] Cardiac arrhythmia0/181/9 Vertigo0/181/9 Hyponatremia0/181/9Chen et al. \[[@CR47]\] Hypotension0/302/36 Respiratory depression0/302/36 Liver dysfunction0/300/36 Bone marrow suppression1/300/36 Hyperammonemia4/300/36Mehta et al. \[[@CR43]\] Hypotension0/2010/20 Respiratory depression0/2012/20Malamiri et al. \[[@CR53]\] Hypotension1/300/30 Respiratory depression0/301/30 Lethargy3/3017/30 Vomiting3/304/30Table 7Adverse event reporting in four comparative non-randomized studies of valproate in status epilepticusStudyAdverse eventPatient numbers in the VPA armTripathi et al. \[[@CR49]\]Hypotension0/41Respiratory depression0/41Liver dysfunction0/41Thrombocytopenia0/41Tiamkao and Sawanyawisuth \[[@CR48]\]Adverse effects not reportedKalita et al. \[[@CR50]\]Adverse effects not reportedAlvarez et al. \[[@CR51]\]Adverse effects not reportedTable 8Adverse event reporting in other clinical studies on valproate in status epilepticusStudyNMain safety findingsCampistol et al. \[[@CR31]\]19No evidence of important side effects; hyperammonemia, somnolence (two subjects each); thrombocytopenia/lymphopenia (one subject); no hypotensionCzapiński and Terczyński \[[@CR30]\]20No adverse events in ten subjects; nausea, injection site pain, abdominal pain (two subjects each); dizziness, taste perversion, somnolence, tremor (one subject each)Czapiński \[[@CR54]\]40No safety data reportedGiroud et al. \[[@CR29]\]23Moderate, transient decrease in heart rate and blood pressure; no respiratory changes; no local injection reactionsJha et al. \[[@CR36]\]11No adverse events reported; no respiratory depression or hypotensionKatragadda et al. \[[@CR32]\]12Thrombocytopenia in three subjectsLeninger and Hofnagel \[[@CR56]\]6No safety data reportedLimdi et al. \[[@CR39]\]63Hypotension in three subjects; no injection-site reactionsNarayanan and Murthy \[[@CR44]\]2Adverse events not reported by treatment groupNaritoku \[[@CR34]\]10One case of hyperammonemia; no hypotensionOlsen et al. \[[@CR45]\]41One case of moderate hypotension; no other side effects observedPatel and Jha \[[@CR38]\]10No adverse events reportedPeters and Pohlmann-Eden \[[@CR40]\]35No severe side effects; mild side effects in seven subjects (dizziness, skin reaction, nausea, fatigue, tremor); no hypotensionPrice et al. \[[@CR61]\]11One case of thrombocytopeniaRamsay et al. \[[@CR65]\]10No cardiovascular, hematological, or subjective side effectsRosenow and Knake \[[@CR35]\]27No adverse events reportedShort \[[@CR59]\]7Hyperammonemia in one subject; sedation and hypotension in two subjectsÜberall et al. \[[@CR33]\]41No drug-related systemic or local side effects. No biological changesYu et al. \[[@CR37]\]18No significant changes in heart rate or blood pressure; one case of transient tremorChen et al. \[[@CR47]\]48No evidence for valproate-related systemic or local side effectsTiamkao and Sawanyawisuth \[[@CR48]\]32Adverse effects not systematically reported

No effects on respiratory function were noted. Cardiovascular effects were limited to slight hypotension reported in five patients overall; this was generally mild and transient, and effects of co-medication were suspected in some cases. The local tolerability of intravenous valproate was also good, with only two subjects reporting injection-site pain. Mild hyperammonemia and mild thrombocytopenia were reported in four patients each.

### Case Reports {#Sec23}

A number of case reports have appeared in the literature describing idiosyncratic adverse reactions to intravenous valproate in patients with SE. Several of these have described cases of encephalopathy. For example, Rossetti and Bromfield \[[@CR76]\] have described two patients developing acute encephalopathy within 48 h of receiving intravenous valproate for the treatment of SE. Serum valproate concentrations were in the therapeutic range. In these cases, encephalopathy was associated with hyperammonemia twofold higher than normal. Symptoms resolved after reduction of the valproate dose. Embacher et al. \[[@CR77]\] described a woman who developed symptoms of encephalopathy within 24 h of receiving intravenous valproate. Again, serum valproate levels were not markedly elevated (29 µg/ml), and serum ammonium was within the normal range. The patient recovered completely within 48 h of discontinuation of valproate. Reversible symptoms of encephalopathy, including confusion or lethargy, were observed in three adult patients with absence SE treated with intravenous valproate and who were on maintenance therapy with lamotrigine \[[@CR78]\]. In these patients, the authors related the symptoms to elevated serum levels of lamotrigine due to the well characterized pharmacokinetic interaction between valproate and lamotrigine, whereby valproate inhibits hepatic glucuronidation of lamotrigine.

In addition to these reports of encephalopathy, a case of significant hypotension following intravenous valproate infusion was described in an 11-year-old girl presenting febrile SE following varicella infection and receiving valproate at a dose of 30 mg/kg over 1 h \[[@CR79]\]. This patient had previously received 10 mg of diazepam and then 1.6 mg of lorazepam, shortly before infusion of valproate was initiated in an attempt to control recurrent seizure activity. The contribution of valproate to the onset of hypotension is consequently difficult to determine.

Intravenous administration of valproate can be associated with acute pancreatitis \[[@CR106]\] and with hepatic failure. A case of acute pancreatitis following intravenous valproate administration has been reported, as well as a case of fulminant hepatic failure associated with hemorrhagic shock leading to death in 9-year-old patient with cerebellar syndrome and moderate mental retardation receiving intravenous valproate for the treatment of SE \[[@CR80]\]. Four months after starting valproate treatment (initially as polytherapy up to 600 mg/day and later as monotherapy up to 1,200 mg/day), the child had nausea and vomiting, with subsequent increasing sleepiness and reduced vigilance. Laboratory exams revealed severe liver failure. Post-mortal examinations showed a microvescicular hepatic steatosis with centro- and mediozonal necrosis, hemoperitoneum, retroperitoneal bleeding, and hemorrhage involving pancreas, adrenal glands, and small bowel. The authors did not rule out the presence of underlying metabolic disorders (organic acidemias, mitochondrial disorders, Alper's disease).

### Pharmacovigilance Data {#Sec24}

As of 31 January 2006, a total of 517 medically confirmed adverse drug reactions in 224 patients receiving intravenous valproate had been reported in the worldwide Sanofi-Aventis post-marketing pharmacovigilance database since 1994 \[[@CR81]\]. Given the estimated exposure to intravenous valproate over the period (\>1 million units prescribed per year worldwide), the reporting rate for adverse events was less than one case per 100,000 administrations. It should be noted that the indication for prescription was not necessarily SE in all these cases, and in many cases the indication was not reported. SE was explicitly reported as the reason for prescription in around one-quarter of these cases. Children, again in all indications, accounted for 21 % of the reported events. The most frequently reported adverse drug reactions (between ten and 50 reports each) were hyperammonemia, coma, encephalopathy, metabolic encephalopathy, thrombocytopenia, confusional state, pancreatitis, hepatic failure, somnolence, and EEG abnormalities. Reporting of these events did not necessarily imply that a causal relationship to treatment had been identified. No relevant differences in the distribution of adverse drug reactions were noted between children and adults or between patients known to have received treatment for SE and the others.

Discussion {#Sec25}
==========

The cumulative literature describes the experiences of over 800 patients with various forms of SE treated with intravenous valproate. The overall response rate to abrogate SE was 70.9 % (95 % CI 67.8 to 73.9). This compares favorably to response rates reported in the Veterans Affairs SE Cooperative Study \[[@CR12]\], which ranged from 43.6 % for phenytoin to 64.9 % for lorazepam in early SE, and also to the overall response rates of published literature on intravenous levetiracetam, which is around 70 % \[[@CR19], [@CR20], [@CR82]\], and lacosamide, which is 56 % in recent series \[[@CR21], [@CR22], [@CR83]\]. Response rates to intravenous valproate were better in children than in adults and did not differ between the SE types. In addition, absence seizures, which can be aggravated by phenytoin, responded well to intravenous valproate. The most commonly reported effective doses were between 15 and 45 mg/kg in bolus (6 mg/kg/min) followed by 1--3 mg/kg/h infusion, although in the literature higher infusion rates following initial bolus (up to 5 mg/kg/h) have been reported \[[@CR33]\]. The response rates were even higher in the randomized controlled trials than in the non-randomized trials and retrospective as well as prospective open series. This finding is not easy to explain, since usually non-randomized trials tend to overestimate the treatment effect \[[@CR84]\]. Two other facts may have contributed to this: in a recent meta-epidemiological study on 139 meta-analyses, trials from less developed countries showed more favorable treatment effects than those in developed countries \[[@CR85]\]. Three of the six randomized studies using valproate for SE came from India, one from China, and one from Iran, the latter having the highest response rates (90 %). In addition, the etiology, which is recognized as an important predictor of outcome \[[@CR86], [@CR87]\], is different from that of the more developed countries, with some of the causes more likely to be easy to control \[[@CR88]--[@CR91]\].

A recent systematic review compared the relative efficacy of five AEDs (valproate, lacosamide, levetiracetam, phenobarbital, phenytoin) in treatment of benzodiazepine-resistant convulsive SE \[[@CR107]\]. A dichotomous outcome analysis of a single group estimate was performed for each AED with regards to cessation of seizure activity. The efficacy of valproate was higher (75.7 %; 95 % CI 63.7--84.8) than that of other AEDs (lacosamide: analysis not performed due to insufficient data; levetiracetam: 68.5 %, 95 % CI 56.2--78.7; phenobarbital 73.6 %, 95 % CI 58.3--84.8; phenytoin 50.2 %, 95 % CI 34.2--66.1). Considered overall, cumulative data from the literature are therefore consistent with valproate being a safe and effective therapeutic option for patients with established SE who have previously failed conventional first-line treatment with benzodiazepines. However, it is important to consider that the methodological heterogeneity of the source literature makes the cumulative response rate reported in our review and previous systematic reviews a relatively imprecise result. Limiting the methodological heterogeneity across studies will be of utmost importance in further research in the treatment of SE: investigators should adopt uniform definitions of SE and its different stages, provide individual patient data, and report their results clearly and explicitly \[[@CR62]\].

Studies of the safety of intravenous valproate administration in patients with SE showed a low incidence of adverse events overall (\<10 %) mainly dizziness, thrombocytopenia, and mild hypotension), which was independent of infusion rates \[[@CR65], [@CR67], [@CR69], [@CR92]\]. There were no unexpected side effects compared with the known safety profile of valproate in other indications using oral administration. The low overall incidence of adverse events following infusion, especially the good cardiovascular and respiratory tolerability even in high doses and fast infusion rates up to 30 mg/kg at 10 mg/kg/min \[[@CR69]\], of intravenous valproate observed in these studies is all the more noteworthy in that the patients often had multiple morbidities and in some cases had recently received, or were still receiving, other AEDs.

The most serious concern relates to the possibility of acute encephalopathy, sometimes related to hepatic abnormalities or hyperammonemia. This idiosyncratic effect may occur when serum valproate concentrations are in the normal therapeutic range (50--110 µg/ml). However, the number of reported cases is relatively low, and most seem reversible on reduction of the dose of valproate or interruption of treatment. In any case, continued or regular periodic monitoring of the EEG during the stabilization period is desirable for all patients with SE \[[@CR93]\], and this can be exploited to detect possible encephalopathy at an early stage. Furthermore, clinicians should monitor lipase, amylase (risk of pancreatitis), ammonium, and transaminase levels. Given the potentially serious or even fatal consequences of not abrogating seizure activity rapidly in SE, the ratio of benefit to risk seems clearly in favor of treatment. Pre-treatment with barbiturates, topiramate, or combinations of both may increase the risk of acute encephalopathy \[[@CR94]--[@CR98]\]. The mechanisms leading to acute encephalopathy are not well understood, but hitherto unrecognized mitochondrial dysfunction may play a crucial role \[[@CR77], [@CR99]\]. Thus, valproate should be used with caution in unexplained SE in children.

Intravenous valproate has several other potential advantages for use as a treatment for established SE. Unlike phenytoin and phenobarbital, it does not require organic solvents for dissolution, minimizing the risk of injection-site reactions such as 'purple glove'. Thus, valproate can be injected at a physiological pH without incompatibility with other commonly used intravenous solutions. The pharmacokinetics of valproate is well characterized \[[@CR100]\], and the transition from intravenous to oral therapy can be made smoothly once SE has been controlled and the patient returns to the community \[[@CR101]\]. Finally, valproate is a broad-spectrum AED that can be used effectively in virtually all types of epilepsy, and safely in patients whose seizure type is poorly characterized \[[@CR101], [@CR102]\]. As such, it would potentially be of particular interest in, for example, absence status, where phenytoin is contraindicated.

Acute treatment of SE is responsible for a high proportion of hospital costs associated with epilepsy. A pharmacoeconomic study conducted in Germany (population 82 million) evaluated that SE causes hospital costs of more than €83 million each year, around one-quarter of the total of epilepsy-related inpatient treatment costs (€342 million); these costs far exceed those for a newly established diagnosis of epilepsy (€49 million) \[[@CR108]\]. Although to date no single study has performed a formal assessment of intravenous valproate treatment versus hospital admission and stay, it is reasonable to hypothesize that prompt seizure control may result in lower economic burden to the healthcare system. However, comparative studies are required to determine which AED has the more favorable efficacy/safety/cost profile in the treatment of SE.

Conclusions {#Sec26}
===========

Intravenous valproate appears to be an effective and safe therapeutic option for patients with established SE who have previously failed conventional first-line treatment with benzodiazepines. However, to inform clinical decision making appropriately, a randomized controlled trial comparing the available treatment options in established SE is needed. Starting from the 2nd London Innsbruck Colloquium of Status Epilepticus \[[@CR103]\], a trial protocol has been presented and subsequently developed by a group of researchers from the USA and Europe \[[@CR104], [@CR105]\]. Once the tribulations of funding this study are overcome, results can be expected in a few years from now.
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